US › Healthcare

Allarity Therapeutics Inc (ALLR)

US · Healthcare · Biotechnology

$1.16+0.43%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-3.4M

EPS

$-0.21

EPS estimate

$-0.25

EPS came in at -0.21 against a street estimate of -0.25 — a beat of 16.0%.

Key statistics

Market cap

$17.7M

Forward P/E

0.0

P/B

5.26

Book value

$0.22

EPS (TTM)

$-0.76

52-week high

$1.84

52-week low

$0.77

50-day MA

$1.29

200-day MA

$1.24

Beta

0.56

Analyst view

Analysts rate Allarity Therapeutics Inc a hold (0 buy, 1 hold, 0 sell out of 1) with an average price target of $10.25.

Shareholding

Insiders

4.19%

Institutions

8.05%

Largest institutional holders

Fund	Stake
Renaissance Technologies Corp	1.43%
Geode Capital Management, LLC	1.20%
Vanguard Capital Management, LLC	1.08%
State Street Corp	0.86%
Militia Capital Management, LLC	0.62%
Citadel Advisors Llc	0.58%
Vanguard Fiduciary Trust Co	0.47%
Northern Trust Corp	0.30%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Allarity Therapeutics Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.